文章：

乳腺癌幸存者罹患非霍奇金淋巴瘤的风险：一项全国性队列研究

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study

原文发布日期：2021-12-14

DOI: 10.1038/s41408-021-00595-0

类型: Article

开放获取: 是

英文摘要：

Several studies have suggested that estrogens have a protective function against lymphomagenesis. The treatment of breast cancer is driven by subtype classification, and the assessment of hormone receptor status is important for treatment selection. Thus, we evaluated the association between breast cancer and the incidence of NHL. We conducted a retrospective cohort study using a population-based nationwide registry in South Korea. We selected all women with newly diagnosed breast cancer between January 1st, 2002 and December 31st, 2016 who received curative treatment (N = 84,969) and a 1:10 sample of age-matched non-breast cancer controls (N = 1,057,674). Incident breast cancer (time-varying exposure) was the exposure and development of any type of NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mature T/NK-cell lymphomas, anaplastic large cell lymphoma (ALCL), and unspecified types of NHL, was the outcome. During follow-up, 1564 incident cases of NHL occurred. The fully adjusted Hazard Ratio (HR) for NHL associated with the development of breast cancer was 1.64 (95% CI = 1.34–2.00) after adjusting for body mass index, alcohol intake, physical activity, smoking, income, and comorbidity. The adjusted HR for NHL was much higher in participants who were aged <50 years and who received hormone therapy (either tamoxifen or aromatase inhibitors) than in those ≥50 years or who did not receive hormone therapy, respectively. The development of breast cancer was associated with a significantly increased risk of NHL, particularly follicular lymphoma and mature T/NK-cell lymphoma. In particular, the risk of NHL was higher in patients receiving hormone therapy and in younger patients.
 

摘要翻译： 

多项研究表明，雌激素对淋巴瘤发生具有保护作用。乳腺癌的治疗需依据亚型分类进行，而激素受体状态的评估对治疗方案选择至关重要。为此，我们评估了乳腺癌与非霍奇金淋巴瘤发病率之间的关联。我们利用韩国全国性人群登记数据库开展了一项回顾性队列研究，筛选了2002年1月1日至2016年12月31日期间所有接受根治性治疗的新确诊乳腺癌女性患者（N=84,969），并按1:10比例匹配了同龄非乳腺癌对照组（N=1,057,674）。研究将新发乳腺癌（时变暴露）作为暴露因素，将包括弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、成熟T/NK细胞淋巴瘤、间变性大细胞淋巴瘤及未指定类型的非霍奇金淋巴瘤在内的各类NHL发病作为结局指标。随访期间共出现1564例NHL新发病例。在调整体质指数、饮酒量、体力活动、吸烟状况、收入及合并症后，乳腺癌患者发生NHL的完全调整风险比为1.64（95%置信区间=1.34–2.00）。年龄<50岁及接受激素治疗（他莫昔芬或芳香化酶抑制剂）的参与者，其NHL调整风险比分别显著高于≥50岁或未接受激素治疗的群体。乳腺癌的发生与NHL风险显著升高相关，尤其是滤泡性淋巴瘤和成熟T/NK细胞淋巴瘤。特别值得注意的是，接受激素治疗的患者及年轻患者的NHL风险更高。

原文链接：

Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study